GSK Sales, Core Earnings Expected to Fall -- Earnings Preview
CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...
infectiousdiseaseadvisor.com23h
Prefilled Syringe Presentation of Shingrix Under FDA Review
The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
Is it game over for the GSK share price?
Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...
EU approves first long-acting HIV treatment for teens
LONDON - The European Commission has authorized the use of Vocabria and Rekambys, a long-acting injectable regimen, for adolescents living with HIV-1, ViiV Healthcare, majority-owned by GSK (NYSE: GSK ...
Pharmabiz6d
EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles
EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...
Hosted on MSN6d
GSK and University of Oxford partner for cancer vaccine research
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...